2-(3-oxobutanoylamino)benzoic acid | CAS:35354-86-0

We serve 2-(3-oxobutanoylamino)benzoic acid CAS:35354-86-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-(3-oxobutanoylamino)benzoic acid

Chemical Name: 2-(3-oxobutanoylamino)benzoic acid
CAS.NO:35354-86-0
Synonyms:2-(Acetoacetamido)benzoic Acid;N-Acetoacetyl-anthranilsaeure;2-(Acetoacetamido)benzoic Acid Hydrate;N-(ACETOACETYL)ANTHRANILIC ACID;N-Acetoacetylanthranilic Acid
Molecular Formula:C11H11NO4
Molecular Weight:221.20900
 
Physical and Chemical Properties:
Density:1.1320
Boiling point:478.7ºC at 760 mmHg
Melting point:86.6℃
Flash point:162.7℃
Index of Refraction:1.603
 
Specification:
Appearance:White crystal powder
Purity:≥99.0%
 
Packing: 25kg drum
Storage:Ware house ventilation and low temperature drying
Application: Mainly used in synthetic pigments, dye couplings.



Contact us for information like 2-(3-oxobutanoylamino)benzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-Acetoacetylanthranilic Acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-Acetoacetyl-anthranilsaeure Use and application,2-(Acetoacetamido)benzoic Acid technical grade,usp/ep/jp grade.


Related News: The primary endpoint of INSPIRE is overall survival. The trial continued beyond the pre-specified interim analysis and is nearing its conclusion.Thiophene-2-ethylamine manufacturer Citizens and residents will be allowed entry to New Zealand, but will be required to quarantine themselves for 14 days, Prime Minister Jacinda Ardern said.(S)-2,2-Dimethylcyclopropanecarboxylic acid supplier API and raw material are often confused due to the similar usage of the two terms.1-Chloro-3-Iodopropane vendor Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said.